LG Builds Global Oncology Ambitions With Novel Frontier Asset
Deal for first-in-class covalent p53 Y220C activator from Frontier's platform pushes Korean firm further along road to becoming global oncology player.
Scrip - April 3, 2026

Execs On The Move: March 23–27, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - April 2, 2026

Whoop Raises $575M At $10.1Bn Valuation With Abbott on Board As Oura And Google Close In
The company, which ships to 56 countries and operates in six languages, said it ended last year booking deals at an annual pace of about $1.1 billion– up 103% year over year – and said it is hiring for more than 600 new roles globally in 2026.
Medtech Insight - April 2, 2026

Force Majeure, 35% Spike In Plastics Costs: Middle East Conflict Hits Medical Supply Chains
Five weeks into the Middle Eastern war, petrochemical force majeure declarations are being filed, prices for a key petrochemical used in plastics are up 35% and the supply chains that produce IV bags, syringes and catheters are under compounding pressure.
Medtech Insight - April 2, 2026

China Issues Global-First Approval For SPECT/CT Imaging Agent For Tumor Diagnosis
The technetium-99m labeled, integrin ?V?3-targeting 99mTc-3PRGD2 has been approved in China as the world’s first SPECT/CT imaging agent for the diagnosis of tumors.
Medtech Insight - April 2, 2026

Bayer’s Men’s Pre-Conception Health Multivitamin Ad Claims Fail To Launch In NAD Review
NAD recommends Bayer HealthCare pull express claims including “Men’s Pre-Conception Health Complete Multivitamin to Support Healthy Sperm designed to provide nutritional support while trying to conceive.”
HBW Insight - April 3, 2026

Who’s Hired? Watson Returns As Apotex CEO
The latest off-patent industry appointments have seen Jeff Watson return as president and CEO of Apotex and Pamela Hoffman take the title of CEO of Padagis, while Australia’s GBMA and Medicines for Ireland have announced new leadership.
Generics Bulletin - April 2, 2026

Teva Clarifies Operations Stable After Neot Hovav Strike
Teva has confirmed no operational impact after a missile-related incident near its Neot Hovav site, countering reports that raised concerns over supply chain risk and manufacturing resilience amid escalating regional tensions.
Generics Bulletin - April 2, 2026

Amarin Insists Skinny Labels Are Not A Safe Harbor
Amarin is asking the US Supreme Court to uphold the Federal Circuit in its Hikma dispute, arguing that skinny-label carve-outs do not shield generics from inducement liability when broader marketing conduct encourages patented uses.
Generics Bulletin - April 2, 2026

Europe’s Biotech Edge Lies In Science-First Investing
Despite tough markets and geopolitical uncertainty, Matthieu Coutet sees strong deal flow, rising investor appetite and big opportunities in fibrosis, with Sofinnova Partners taking an active role in building companies through series A and beyond.
In Vivo - April 2, 2026